SCHEMBL6428842

SCHEMBL6428842

N#Cc1ccc(NC(=O)c2ccc([N+](=O)[O-])o2)cc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.64
MEN1 O00255 2/20 0.64
DDIT3 P35638 6/20 0.62
STING1 Q86WV6 1/20 0.62
RAB9A P51151 4/20 0.61
LMNA P02545 2/20 0.61
MAPT P10636 2/20 0.61
KDM4E B2RXH2 1/20 0.61
HTT P42858 1/20 0.61
NPC1 O15118 3/20 0.60
MITF O75030 1/20 0.60
GAA P10253 1/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
POLB P06746 1/20 0.59
JAK2 O60674 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24290767 0.89 KMT2A (0.78) KMT2AMEN1DDIT3STING1RAB9A
SCHEMBL22822607 0.85 JAK2 (0.68) KMT2AMEN1DDIT3RAB9ALMNA
SCHEMBL22804212 0.83 KMT2A (0.71) KMT2AMEN1DDIT3STING1RAB9A
SCHEMBL7715858 0.82 KMT2A (0.69) KMT2AMEN1DDIT3STING1RAB9A
SCHEMBL14584254 0.82 MEN1 (0.69) KMT2AMEN1DDIT3STING1RAB9A
SCHEMBL13219511 0.82 KMT2A (0.70) KMT2AMEN1DDIT3STING1RAB9A
SCHEMBL22822765 0.82 MEN1 (0.73) KMT2AMEN1DDIT3STING1RAB9A
SCHEMBL24292214 0.82 MEN1 (0.73) KMT2AMEN1DDIT3STING1RAB9A
SCHEMBL13219524 0.82 LMNA (0.77) KMT2AMEN1DDIT3STING1RAB9A
SCHEMBL13219564 0.82 RAB9A (0.69) KMT2AMEN1DDIT3STING1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428389-B2 Diarylamide compound and application thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2025-09-30 US claimed
US-20230045031-A1 Diarylamide Compound and Application Thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-02-09 US claimed
EP-3984534-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF Peking University (CN) 2022-04-20 EP claimed
CN-112107568-B Diaryl amide compound and application thereof 北京龙嘉博创医药科技有限公司 2022-03-25 CN claimed
WO-2020253802-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF 北京大学 2020-12-24 WO claimed
CN-112107568-A Diaryl amide compound and application thereof 北京大学 2020-12-22 CN claimed
US-20050026968-A1 Heterocyclic amides with anti-tuberculosis activity UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-02-03 US claimed
US-12428389-B2 Diarylamide compound and application thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2025-09-30 US disclosed
US-20230045031-A1 Diarylamide Compound and Application Thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-02-09 US disclosed
US-20230045031-A1 Diarylamide Compound and Application Thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-02-09 US disclosed
EP-3984534-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF Peking University (CN) 2022-04-20 EP disclosed
EP-3984534-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF Peking University (CN) 2022-04-20 EP disclosed
CN-112107568-B Diaryl amide compound and application thereof 北京龙嘉博创医药科技有限公司 2022-03-25 CN disclosed
WO-2020253802-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF 北京大学 2020-12-24 WO disclosed
WO-2020253802-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF 北京大学 2020-12-24 WO disclosed
CN-112107568-A Diaryl amide compound and application thereof 北京大学 2020-12-22 CN disclosed
EP-3502102-A1 STING INHIBITORS ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2019-06-26 EP disclosed
US-20050222408-A1 Heterocyclic amides with anti-tuberculosis activity UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-10-06 US disclosed
US-20050026968-A1 Heterocyclic amides with anti-tuberculosis activity UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222408-A1 Heterocyclic amides with anti-tuberculosis activity TST, KAT5, NDUFS5 KMT2A 2545/4885MEN1 4703/4885DDIT3 2371/4885
US-12428389-B2 Diarylamide compound and application thereof SLC14A1, SLC28A1, SLC28A2 KMT2A 3036/4885MEN1 3485/4885DDIT3 723/4885
US-20050026968-A1 Heterocyclic amides with anti-tuberculosis activity TST, KAT5, HDAC5 KMT2A 2476/4885MEN1 4749/4885DDIT3 2137/4885
US-20230045031-A1 Diarylamide Compound and Application Thereof SLC14A1, SLC28A1, SLC28A2 KMT2A 3036/4885MEN1 3485/4885DDIT3 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.